Key result
Low-dose aspirin use was not associated with improved cumulative survival compared to no aspirin in patients on hemodialysis (log rank P=0.299).
Why the study?
Does aspirin 100 mg/d reduce all-cause mortality and cardiovascular events in patients on hemodialysis?
Population
406 patients on regular hemodialysis (HD)
Comparison
Aspirin 100 mg/d vs No aspirin (propensity-matched)
Design
Cohort
Follow-up
5 years
Authors
Loading...
Aspirin should not yet inform CVD prevention in hemodialysis; leaves open efficacy pending randomized trials.
Cohort (n=406)
Does aspirin 100 mg/d reduce all-cause mortality and cardiovascular events in patients on hemodialysis?
p-value: p=0.299
Low-dose aspirin does not appear to provide significant cardiovascular or mortality benefits for patients undergoing hemodialysis.
Liu et al. (2016) conducted a cohort in chronic kidney disease undergoing hemodialysis (n=406). Aspirin vs. No aspirin was evaluated on All-cause death, cardiovascular events, hemorrhage, and ischemic stroke (p=0.299). Low-dose aspirin use was not associated with improved cumulative survival compared to no aspirin in patients on hemodialysis (log rank P=0.299).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: